Abstract
Prostate specific antigen (PSA) is an exceptional biomarker for prostate cancer. While there has been a significant decrease in prostate cancer mortality since the introduction of PSA screening, the benefit of screening can be diminished by the loss of quality of life (QoL) stemming from both the diagnosis itself and the adverse effects of treatment. This article quantifies the effects of screening strategies on prostate cancer mortality and QoL.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
